| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10493028 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
| US10959947 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
| US10959948 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
| US10959949 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
| US10688046 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
| US10959946 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
| US11638692 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | |
Firvanq Kit is owned by Azurity.
Firvanq Kit contains Vancomycin Hydrochloride.
Firvanq Kit has a total of 7 drug patents out of which 0 drug patents have expired.
Firvanq Kit was authorised for market use on 26 January, 2018.
Firvanq Kit is available in for solution;oral dosage forms.
Firvanq Kit can be used as treatment of c. difficile-associated diarrhea, treatment of staphylococcal enterocolitis.
The generics of Firvanq Kit are possible to be released after 13 March, 2035.
Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient
Market Authorisation Date: 26 January, 2018
Treatment: Treatment of staphylococcal enterocolitis; Treatment of c. difficile-associated diarrhea
Dosage: FOR SOLUTION;ORAL
FIRVANQ KIT family patents
